OnKure is a biotechnology company commercializing a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solid tumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies. OnKure advancing the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.

from http://onkure.shockingcreations.com/

Patents 16show all

  • 5
    A61K - Preparations for medical, dental, or toilet purposes
  • 5
    C07D - Heterocyclic compounds
  • 5
    C07K - Peptides

Clinical Trials 1show all

1Phase 1

SEC Filings show all


Contact Information

1105 Spruce Street
Boulder, CO 80302
United States


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-05-02$7,000,000Series ADelian CapitalOnKure management
2015-07-07$495,000Debt Financing

Key Executives

  • Anthony D. Piscopio
    Executive Officer, Director
  • Xuedong Liu
    Executive Officer, Director
  • Ken Peak
    Executive Officer, Director
  • Donna Peak
    Executive Officer, Director
  • Joseph Romano